LEADER 00741nam0-2200277---450-
001 990009398380403321
005 20110715091717.0
035   $a000939838
035   $aFED01000939838
035   $a(Aleph)000939838FED01
035   $a000939838
100   $a20110715d1960----km-y0itay50------ba
101 0 $afre
102   $aFR
105   $aa-------001yy
200 1 $a<<L'>>amour en Grèce$fRobert Flacelière
210   $aParis$cHachette$d1960
215   $a258 p.$cill.$d22 cm
700  1$aFlacelière,$bRobert$f<1904-1982>$0388002
801  0$aIT$bUNINA$gRICA$2UNIMARC
901   $aBK
912   $a990009398380403321
952   $aDirez. F-013$b11181 ddr$fDDR
959   $aDDR
996   $aAmour en Grèce$9765234
997   $aUNINA

LEADER 01191nam--2200361---450-
001 990003270100203316
005 20090612111012.0
010   $a978-1-84720-599-5
035   $a000327010
035   $aUSA01000327010
035   $a(ALEPH)000327010USA01
035   $a000327010
100   $a20090612h2008----km-y0itay50------ba
101   $aeng
102   $aUS
105   $a||||||||001yy
200 1 $aCompetition law and patents$ea follow-on innovation perspective in the biopharmaceutical industry$fIrina Haracoglou
210   $aCheltenham, UK [etc.]$cEdward Elgar$dcopyr. 2008
215   $aXX, 251 p.$d24 cm
225 2 $aNew horizons in competition law and economics
410  0$12001$aNew horizons in competition law and economics
606 0 $aProprietà industriale$xLegislazione$2BNCF
676   $a341.758
700  1$aHARACOGLOU,$bIrina$0604842
801  0$aIT$bsalbc$gISBD
912   $a990003270100203316
951   $aXXIII.3.E 7$b59210 G.$cXXIII.3.E$d00226311
959   $aBK
969   $aGIU
979   $aIANNONE$b90$c20090612$lUSA01$h1110
979   $aCHIARA$b90$c20100419$lUSA01$h0951
996   $aCompetition law and patents$91119302
997   $aUNISA